WO2009019427A1 - Leptin fusion proteins - Google Patents

Leptin fusion proteins Download PDF

Info

Publication number
WO2009019427A1
WO2009019427A1 PCT/GB2008/002489 GB2008002489W WO2009019427A1 WO 2009019427 A1 WO2009019427 A1 WO 2009019427A1 GB 2008002489 W GB2008002489 W GB 2008002489W WO 2009019427 A1 WO2009019427 A1 WO 2009019427A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
polypeptide
seq
leptin
acid sequence
Prior art date
Application number
PCT/GB2008/002489
Other languages
French (fr)
Inventor
Peter Artymiuk
Richard Ross
Jon Sayers
Original Assignee
Asterion Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Limited filed Critical Asterion Limited
Priority to CN200880110351A priority Critical patent/CN101827858A/en
Priority to JP2010519503A priority patent/JP2010535486A/en
Priority to EP08776011A priority patent/EP2185585A1/en
Priority to US12/671,979 priority patent/US20110092417A1/en
Publication of WO2009019427A1 publication Critical patent/WO2009019427A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the invention relates to leptin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.
  • Cytokine receptors can be divided into three separate groups.
  • Class 1 (referred to as the haemotopoietin or growth hormone family) receptors are characterised by four conserved cysteine residues in the amino terminal part of their extracellular domain and the presence of a conserved Trp-Ser-Xaa-Trp-Ser motif in the C-terminal part.
  • the receptors consist of two polypeptide chains.
  • Class I receptors can be sub-divided into the GM-CSF sub-family (which includes IL-3, IL-5, GM-CSF, GCSF) and IL-6 sub-family (which includes IL-6, IL-11 and IL-12).
  • IL-6 sub-family there is a common tranduscing subunit (gp130) that associates with one or two different cytokine subunits.
  • IL-2 sub-family includes IL-2, IL-4, IL-7, IL-9 and IL-15.
  • the repeated Cys motif is also present in Class 2 (interferon receptor family) the ligands of which are ⁇ , ⁇ and y interferons but lack the conserved Trp-Ser- Xaa-Trp-Ser motif.
  • Human leptin is a 16kD protein hormone encoded by the lep gene in humans and the ob gene in mice. Leptin acts through the leptin receptor which is a single transmembrane receptor of the cytokine family. There is a single gene that encodes leptin in humans which includes three exons and two introns and spans about 18kb of genomic DNA. Leptin links nutritional status and the immune system to control, inter alia, appetite and the immune function. The existence of mutations in either leptin or leptin receptor can result in an obese phenotype with attendant secondary symptoms associated with obesity (e.g. heart disease, diabetes type II).
  • obesity e.g. heart disease, diabetes type II
  • Leptin is mainly produced by adipose tissue in proportion to the body mass index (BMI) and, at lower levels, by organs such as the stomach and placenta. Leptin regulates body weight through inhibition of food intake and stimulation of energy expenditure. Moreover, leptin affects both the innate and adaptive immunity. On innate immunity, leptin modulates the activity of neutrophils, increases the phagocytosis of monocytes/macrophages and enhances the secretion of inflammatory mediators of the acute-phase response.
  • BMI body mass index
  • leptin affects both the innate and adaptive immunity. On innate immunity, leptin modulates the activity of neutrophils, increases the phagocytosis of monocytes/macrophages and enhances the secretion of inflammatory mediators of the acute-phase response.
  • leptin On adaptive immunity, leptin promotes proliferation and interleukin 2 (IL-2) secretion by na ⁇ ve T cells whereas on memory T cells, it promotes the switch towards T helper 1 (Th1) immune response by increasing interferon- ⁇ (INF- ⁇ ) and tumor necrosis factor- ⁇ (TNF- ⁇ secretion). If leptin expression and/or production is perturbed then the pathological manifestation of disease is complicated with effects on energy metabolism and immune status. Apart from the established linkage to obesity, reduction in leptin is associated with infertility, osteoporosis and immune suppression.
  • This disclosure relates to the identification of leptin recombinant forms that have improved pharmacokinetics (PK) and activity.
  • the new leptin molecules have biological activity, form dimers and have improved stability.
  • nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide that has the activity of leptin comprising a leptin polypeptide linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
  • a fusion polypeptide comprising: the amino acid sequence of the leptin polypeptide, or active part thereof linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
  • said fusion polypeptide comprises two leptin binding domains.
  • said fusion polypeptide comprises an immunoglobulin-like domain.
  • said fusion polypeptide comprises at least one cytokine-like homology domain; preferably two cytokine-like homology domains.
  • said fusion polypeptide comprises at least one fibronectin III binding domain; preferably two fibronectin III binding domains.
  • said fusion polypeptide comprises amino acid residues 428-535 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 536-635 of SEQ ID NO: 41. In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 326-437 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 62-178 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 235-325 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 639-732 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 734-829 of SEQ ID NO: 41.
  • said fusion polypeptide comprises amino acid residues 428-635 of SEQ ID NO: 41.
  • said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned amino-terminal to said leptin binding domain in said fusion polypeptide.
  • said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned carboxyl-terminal to said leptin binding domain in said fusion polypeptide.
  • said leptin polypeptide is linked to at least one binding domain of the leptin receptor polypeptide by a peptide linker; preferably a flexible peptide linker.
  • said peptide linking molecule comprises at least one copy of the peptide GIy GIy GIy GIy GIy Ser.
  • said peptide linking molecule comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 copies of the peptide GIy GIy GIy GIy Ser.
  • said peptide linking molecule consists of 6 copies of the peptide GIy GIy GIy GIy Ser.
  • said peptide linking molecule consists of 8 copies of the peptide GIy GIy GIy GIy GIy Ser.
  • said polypeptide does not comprise a peptide linking molecule and is a direct fusion of leptin polypeptide and at least one leptin binding domain of the leptin receptor polypeptide.
  • nucleic acid molecule comprising a nucleic acid sequence selected from: i) a nucleic acid sequence as represented in SEQ ID NO:3 ; ii) a nucleic acid sequence as represented in SEQ ID NO:5; iii) a nucleic acid sequence as represented in SEQ ID NO:7; iv) a nucleic acid sequence as represented in SEQ ID NO:9; v) a nucleic acid sequence as represented in SEQ ID NO:11 ; vi) a nucleic acid sequence as represented in SEQ ID NO: 13; vii) a nucleic acid sequence as represented in SEQ ID NO:15; viii) a nucleic acid sequence as represented in SEQ ID NO:17; ix) a nucleic acid sequence as represented in SEQ ID NO: 19; x) a nucleic acid sequence as represented in SEQ ID NO:21 ; xi) a nucleic acid sequence as represented in SEQ ID NO:
  • nucleic acid molecule encodes a leptin agonist.
  • said nucleic acid molecule encodes a leptin antagonist.
  • Hybridization of a nucleic acid molecule occurs when two complementary nucleic acid molecules undergo an amount of hydrogen bonding to each other.
  • the stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acid molecules used.
  • the T m is the temperature at which 50% of a given strand of a nucleic acid molecule is hybridized to its complementary strand.
  • Hybridization 5x SSC at 65°C for 16 hours
  • Hybridization 5x-6x SSC at 65°C-70°C for 16-20 hours
  • Hybridization 6x SSC at RT to 55°C for 16-20 hours
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO:3 .
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 5.
  • nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 7. In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 9.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 11.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 13.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 17.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 19.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 21.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 23.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 25.
  • said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 27.
  • polypeptide comprising or consisting of an amino acid sequence as represented in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39 or 40.
  • a homodimer consisting of two polypeptides wherein each of said polypeptides comprises: i) a first part comprising leptin, or a receptor binding domain thereof, optionally linked by a peptide linking molecule to ii) a second part comprising at least one leptin binding domain or part thereof, of the leptin receptor.
  • said homodimer comprises two polypeptides comprising or consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39 or 40.
  • a vector comprising a nucleic acid molecule according to the invention.
  • said vector is an expression vector adapted to express the nucleic acid molecule according to the invention.
  • a vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection.
  • the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell.
  • the vector may be a bi- functional expression vector which functions in multiple hosts.
  • promoter is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in eukaryotic or prokaryotic cells.
  • "Operably linked” means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.
  • the promoter is a constitutive, an inducible or regulatable promoter.
  • a cell transfected or transformed with a nucleic acid molecule or vector according to the invention there is provided a cell transfected or transformed with a nucleic acid molecule or vector according to the invention.
  • said cell is a eukaryotic cell.
  • said cell is a prokaryotic cell.
  • said cell is selected from the group consisting of; a fungal cell (e.g. Pichia spp, Saccharomyces spp, Neurospora spp); insect cell (e.g. Spodoptera spp); a mammalian cell (e.g. COS cell, CHO cell); a plant cell.
  • composition comprising a polypeptide according to the invention including an excipient or carrier.
  • said pharmaceutical composition is combined with a further therapeutic agent.
  • compositions of the present invention are administered in pharmaceutically acceptable preparations.
  • Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
  • compositions of the invention can be administered by any conventional route, including injection.
  • the administration and application may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, intra-articuar, subcutaneous, topical (eyes), dermal (e.g a cream lipid soluble insert into skin or mucus membrane), transdermal, or intranasal.
  • compositions of the invention are administered in effective amounts.
  • An "effective amount" is that amount of pharmaceuticals/compositions that alone, or together with further doses or synergistic drugs, produces the desired response. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods.
  • the doses of the pharmaceuticals compositions administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject (i.e. age, sex).
  • the pharmaceutical compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions.
  • salts should be pharmaceutically acceptable, but non- pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
  • Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
  • pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
  • compositions may be combined, if desired, with a pharmaceutically- acceptable carrier.
  • pharmaceutically-acceptable carrier means one or more compatible solid or liquid fillers, diluents or encapsulating substances that are suitable for administration into a human.
  • carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
  • the components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficacy.
  • the pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
  • suitable buffering agents including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
  • compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
  • suitable preservatives such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
  • compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
  • compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound.
  • Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion.
  • compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation that is preferably isotonic with the blood of the recipient.
  • This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 , 3-butane diol.
  • the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono-or di-glycerides.
  • fatty acids such as oleic acid may be used in the preparation of injectables.
  • Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
  • a method to treat a human subject suffering from a condition that would benefit from administration of a leptin agonist comprising administering an effective amount of at least one polypeptide according to the invention.
  • said condition is obesity
  • said condition is an obesity related condition.
  • said obesity related condition is type Il diabetes. In a preferred method of the invention said obesity related condition is heart disease.
  • said condition is immune suppression.
  • a method to treat a human subject suffering from a condition that would benefit from administration of a leptin antagonist comprising administering an effective amount of at least one polypeptide according to the invention.
  • said condition is anorexia. In a further preferred method of the invention said condition is an autoimmune disease.
  • said autoimmune disease is selected from the group consisting of: multiple sclerosis, type 1 diabetes, autoimmune thyroid disease, autoimmune hepatitis, rheumatoid arthritis, autoimmune colitis, crohns disease, celiac disease, autoimmune nephritis, autoimmune neuropathy (guillan Barre), encephalopathy (Rasmussen), fibrosing alveolitis.
  • polypeptide is administered intravenously.
  • polypeptide is administered subcutaneously.
  • polypeptide is administered at two day intervals; preferably said polypeptide is administered at weekly, 2 weekly or monthly intervals.
  • a monoclonal antibody that binds the polypeptide or dimer according to the invention.
  • said monoclonal antibody is an antibody that binds the polypeptide or dimer but does not specifically bind leptin or leptin receptor individually.
  • the monoclonal antibody binds a conformational antigen presented either by the polypeptide of the invention or a dimer comprising the polypeptide of the invention.
  • a method for preparing a hybridoma cell-line producing monoclonal antibodies comprising the steps of: i) immunising an immunocompetent mammal with an immunogen comprising at least one polypeptide according to the invention; ii) fusing lymphocytes of the immunised immunocompetent mammal with myeloma cells to form hybridoma cells; iii) screening monoclonal antibodies produced by the hybridoma cells of step
  • the said immunocompetent mammal is a mouse.
  • said immunocompetent mammal is a rat.
  • hybridoma cell-line obtained or obtainable by the method according to the invention.
  • Figure 1a is the nucleic acid sequence of bacterial expressed leptin;
  • Figure 1b is the amino acid sequence;
  • Figure 2a is the nucleic acid sequence of LR 2A1 ;
  • Figure 2b is the amino acid sequence of LR 2A1 ;
  • Figure 3a is the nucleic acid sequence of LR 2A1 ;
  • Figure 2b is the amino acid sequence of LR 2A1 adapted for bacterial expression;
  • Figure 4a is the nucleic acid sequence of LR 2B1 ;
  • Figure 2b is the amino acid sequence of LR 2B1 ;
  • Figure 5a is the nucleic acid sequence of LR 2D1 ;
  • Figure 2b is the amino acid sequence of LR 2D1 ;
  • Figure 6a is the nucleic acid sequence of LR 2E1 ;
  • Figure 2b is the amino acid sequence of LR 2E1 ;
  • Figure 7a is the nucleic acid sequence of LR 2F1 ;
  • Figure 2b is the amino acid sequence of LR 2F1 ;
  • Figure 8a is the nucleic acid sequence of LR 2G1 ;
  • Figure 2b is the amino acid sequence of LR 2G1;
  • Figure 9a is the nucleic acid sequence of LR 2H1 ;
  • Figure 2b is the amino acid sequence of LR 2H1 ;
  • Figure 10a is the nucleic acid sequence of LR 211 ;
  • Figure 2b is the amino acid sequence of LR 211 ;
  • Figure 11a is the nucleic acid sequence of LR 2J1 ;
  • Figure 2b is the amino acid sequence of LR 2J1 ;
  • Figure 12a is the nucleic acid sequence of LR 2K1 ;
  • Figure 2b is the amino acid sequence of LR 2K1 ;
  • Figure 13a is the nucleic acid sequence of LR 2L1 ;
  • Figure 2b is the amino acid sequence of LR 2L1 ;
  • Figure 14 is the nucleic acid sequence of LR 2M1 ;
  • Figure 2b is the amino acid sequence of LR 2M1 ;
  • FIG. 15 a) The leptin binding domain (LBD) is ligated into the expression vector pSecTag to generate pSecTaglinkSSLBD. b) leptin is ligated into pSecTaglinkSSLBD to generate pSecTag2A1(lm). c) DNA is synthesised and ligated into pSecTag2A1(lm) to introduce a (G 4 S) 5 ;
  • Figure 16 Western blot of media from CHO cells expressing leptin LR-fusion.
  • the contents of the lanes are 1 2A1 expression; 2.2B1 expression; 3 2D1 expression; 4. Markers (20, 25, 37, 50, 75, 100, 150, 200 kDa).
  • the western blot was probed with antibodies against leptin.
  • Figure 17 a) The leptin receptor extracellular domains (ObRex) are ligated into the expression vector pSecTag to generate pSecTaglinkSSObRex. b) leptin is ligated into pSecTaglinkSSObRex to generate pSecTag2B1 (lm). c) DNA is synthesised and ligated into pSecTag2B1 (lm) to introduce a (G 4 S) 5 ;
  • Figure 18 a) PCR was used to generate DNA consisting of the gene of interest flanked by suitable restriction sites (contained within primers R1-4). b) The PCR products were ligated into a suitable vector either side of the linker region, c) The construct was then modified to introduce the correct linker, which did not contain any unwanted sequence (i.e. the non-native restriction sites);
  • Figure 19 a) Oligonucleotides were designed to form partially double-stranded regions with unique overlaps and, when annealed and processed would encode the linker with flanking regions which would anneal to the ligand and receptor, b) PCRs were performed using the "megaprimer” and terminal primers (R1 and R2) to produce the LR-fusion gene. The R1 and R2 primers were designed so as to introduce useful flanking restriction sites for ligation into the target vector;
  • Figure 20 is the amino acid sequence of full length leptin receptor;
  • Figure 21 is a schematic diagram of the leptin LR-fusion constructs
  • Figure 22 is an Immuno-blot analysis of CHO FIp-In stable cell lines expressing 2A1 , 2B1 and 2D1 constructs.
  • Figure 23 is expression of 2A1Ecopt.
  • Figure 24 is a Coomassie stained SDS-PAGE gel of the inclusion body prep for 2A1 Ecopt.
  • Figure 25 is an In vitro bioassay of crude media from CHO FIp-In cells expressing 2A1. Crude media (10x concentrate) from CHO FIp-In cells expressing 2A1 was used to stimulate the cells in the leptin in vitro bioassay. The media gave agonistic activity, media from cells not expressing 2A1 gave no activity (black columns); and
  • Figure 26 is an In vitro bioassay of the purified 2A1Ecopt. Refolded 2A1 Ecopt samples which showed a single band at the correct size for 2A1Ecopt in the immuno-blots were used to stimulate the cells in the leptin in vitro bioassay. The samples showed agonistic activity. Materials and Methods
  • Leptin LR-fusions were tested for in vitro activity using a dual-luciferase bioassay. Briefly, MCF-7 mammalian cells were transfected with plasmids expressing firefly luciferase induced by SIE, leptin receptor (ObR), STAT3 and Renilla luciferase (the latter three proteins are constitutively expressed). Twenty-four hours later the cells are stimulated for six hours with the leptin LR-fusion. The cells were lysed and the Firefly luciferase activity measured, this is proportional to the stimulation of the leptin receptor by the LR-fusion. Dividing this value by the activity of the constitutively expressed Renilla luciferase gives an activity corrected for experimental error.
  • Immunoassays that measure the binding of ligand or receptor to polyclonal and monoclonal antibodies are known in the art. Commercially available antibodies are available to detect the ligand or receptor in samples and also for use in competitive inhibition studies. For example, see http://www.abcam.com/index.html. Abeam PLC. Recombinant Production of fusion proteins
  • the components of the fusion proteins were generated by PCR using primers designed to anneal to the ligand or receptor and to introduce suitable restriction sites for cloning into the target vector (Fig X1a).
  • the template for the PCR comprised the target gene and was obtained from IMAGE clones, cDNA libraries or from custom synthesised genes. Once the ligand and receptor genes with the appropriate flanking restriction sites had been synthesised, these were then ligated either side of the linker region in the target vector (Fig X1b).
  • the construct was then modified to contain the correct linker without flanking restriction sites by the insertion of a custom synthesised length of DNA between two unique restriction sites either side of the linker region, by mutation of the linker region by ssDNA modification techniques, by insertion of a primer duplex/multiplex between suitable restriction sites or by PCR modification (FigXic).
  • the linker with flanking sequence designed to anneal to the ligand or receptor domains of choice, was initially synthesised by creating an oligonucleotide duplex and this processed to generate double-stranded DNA (Fig X2a). PCRs were then performed using the linker sequence as a "megaprimer", primers designed against the opposite ends of the ligand and receptor to which the "megaprimer” anneals to and with the ligand and receptor as the templates. The terminal primers were designed with suitable restriction sites for ligation into the expression vector of choice (Fig X2b).
  • Expression was carried out in a suitable system (e.g. mammalian CHO cells, E. coli, etc.) and this was dependant on the vector into which the LR-fusion gene was generated. Expression was then analysed using a variety of methods which could include one or more of SDS-PAGE, Native PAGE, western blotting, ELISA.
  • a suitable system e.g. mammalian CHO cells, E. coli, etc.
  • the RL-fusions were expressed at a larger scale to produce enough protein for purification and subsequent analysis.
  • Purification was carried out using a suitable combination of one or more chromatographic procedures such as ion exchange chromatography, hydrophobic interaction chromatography, ammonium sulphate precipitation, gel filtration, size exclusion and/or affinity chromatography (using nickel/cobalt-resin, antibody-immobilised resin and/or ligand/receptor-immobilised resin).
  • chromatographic procedures such as ion exchange chromatography, hydrophobic interaction chromatography, ammonium sulphate precipitation, gel filtration, size exclusion and/or affinity chromatography (using nickel/cobalt-resin, antibody-immobilised resin and/or ligand/receptor-immobilised resin).
  • Purified protein was analysed using a variety of methods which could include one or more of Bradford's assay, SDS-PAGE 1 Native PAGE, western blotting, ELISA.
  • Denaturing PAGE, native PAGE gels and western blotting were used to analyse the fusion polypeptides and western blotting performed with antibodies non-conformationally sensitive to the LR-fusion.
  • Native solution state molecular weight information can be obtained from techniques such as size exclusion chrmoatography using a Superose G200 analytical column and analytical ultracenthfugation.
  • the 2A1 , 2B1 and 2D1 genes were synthesised by generating the Ob, LBD, ObREc and linker components with unique, compatible restriction sites at either end and ligating them together to form the complete gene. Extraneous sequence (i.e. the restriction sites) in 2B1 and 2D1 were subsequently removed by ligating in custom synthesised DNA fragments (Genecust, France) between unique restriction sites within the Ob, LBD and ObREc genes, this generated 2B2 and 2D2.
  • the 2A1 Ecopt gene was generated by custom DNA synthesis (Genecust, France) and ligated into pET21a+.
  • the 2A1 Ecopt sequence is codon optimised for expression in E. coli and has a C-terminal His tag.
  • Stable cell lines were generated using a modified Invitrogen vector pSecTag-V5/FRT- Hist in 6-well plates using Fugene-6 as the transfection reagent.
  • the CHO FIp-In cells were co-transfected with the expression vector and pOG44, a plasmid that expresses flp recombinase an enzyme which causes the recombination of the LR-fusion gene into a "hot-spot" of the cell chromosome.
  • Hygromycin B was used to select for cells with positive recombinants.
  • E. co// expression pET21a+:2A1 Ecopt was transformed into chemically competent E. coli BL21 (DE3) cells. Clones expressing 2A1 Ecopt were then grown in LB media supplemented with carbenicillin (100 ⁇ g/ml) and grown on a flat bed shaker at room temperature. Induction was performed with 1 mM IPTG at an OD 6 oo of 0.4 and the culture grown for overnight.
  • the cells were then harvested and lysed, samples were then run on SDS-PAGE gels and coomassie stained or immuno-blotted.
  • 2A1 Ecopt was expressed in E. coli BL21 (DE3) cells from the plasmid pET21a+:2A1 Ecopt.
  • 2A1 Ecopt was purified using a Ni-Probond resin column. The insoluble fraction of the lysed cells was washed four times with 2% sodium deoxycholate and the two times with distilled water to give an inclusion body prep. This step removed most of the contaminating proteins giving >80% purity for 2A1 Ecopt; Figure 24. Statistics
  • DNA encoding the leptin binding domain (LBD) domains of the leptin receptor (ObR) flanked by BamHI and Hindlll was produced by PCR. This was then ligated into a modified pSecTag-FRT-V5-His TOPO vector to produce pSecTagLinkSSLBD (Fig 15a).
  • DNA encoding leptin flanked by Nhel and BamHI was produced by PCR using the primers; NheObssF (5'-gggaaagctagccaccatgcattggggaaccctgtgcg-3') and ObBamR (5'-gggaaaggatccgcacccagggctgaggtcc-3').
  • NheObssF 5'-gggaaagctagccaccaccatgcattggggaaccctgtgcg-3'
  • ObBamR 5'-gggaaaggatccgcacccagggctgaggtcc-3'.
  • This was ligated into pSecTagLinkSSLBD to produce pSecTag2A1 (Im) (Fig 15b).
  • the linker region was custom synthesised between AIeI and Nsil restriction sites and this inserted into pSecTag2A1(lm)
  • pSecTag2A1 stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. However western blot of the expression media, using antibodies against leptin, showed 2A1 was expressed (Fig 16). 2A1 was also expressed in Escherichia coli cells. The amino acid sequence for 2A1 was back-translated with optimisation for E. coli codon usage. The codon optimised gene (2A1 Ecopt) was custom gene synthesised and then inserted into the pET21a+ expression vector and the protein expressed from E. coli BL21 (DE3) cells.
  • DNA encoding the leptin receptor extracellular domain (ObRex) flanked by BamHI and Hindlll was produced by PCR. This was then ligated into a modified pSecTag-FRT-V5- His TOPO vector to produce pSecTagLinkSSObRex (Fig 17a).
  • DNA encoding leptin flanked by Nhel and BamHI was produced by PCR using the primers; NheObssF (5'- gggaaagctagccaccatgcattggggaaccctgtgcg-3') and ObBamR (5'- gggaaaggatccgcacccagggctgaggtcc-3').
  • pSecTagLinkSSObRex This was ligated into pSecTagLinkSSObRex to produce pSecTag2B1 (Im) (Fig 17b).
  • the linker region was custom synthesised between AIeI and BstBI restriction sites and this inserted into pSecTag2B1(lm) to give pSecTag2B1stop (Fig 17c).
  • pSecTag2B1stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. Expression levels were determined to be in the low ng/ml levels as measured by ELISA using antibodies against ObR (Table 2). However these expression levels may have been underestimated by the ELISA since the western blot of the expression media suggests that higher levels of expression have been achieved (Fig 16).
  • pSecTag2D1stop was synthesised in a similar way to pSecTag2B1stop, above.
  • pSecTag2B1stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. Expression levels were determined to be in the low ng/ml levels as measured by ELISA using antibodies against ObR (Table 2). However these expression levels may have been underestimated by the ELISA since the western blot of the expression media suggests that higher levels of expression have been achieved (Fig 16).
  • the in vitro bioassay utilises a dual-luciferase reporter system to measure the activity of stimulated MCF-7 cells.
  • MCF-7 cells were transfected with plasmid expressing ObR, STAT5, SIE and Renilla luciferase.
  • Activation of the ObR caused an inducible, proportional expression of firefly luciferase via STAT3 and SIE; the Renilla luciferase was constitutively expressed and acted as a control to normalise the firefly luciferase activity measurement.
  • Both the firefly and Renilla luciferase were measured using the Dual-Luciferase Reporter Assay System (Promega) and a luminometer. Dividing the firefly luciferase measurement by the Renilla luciferase measurement gave a corrected activity (i.e. correction for differences between samples such as cell density and transfection efficiency). The corrected activity was then divided by the activity of un-stimulated cells to give a "fold induction" value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)

Abstract

The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Description

LEPTIN FUSION PROTEINS
The invention relates to leptin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.
Cytokine receptors can be divided into three separate groups. Class 1 (referred to as the haemotopoietin or growth hormone family) receptors are characterised by four conserved cysteine residues in the amino terminal part of their extracellular domain and the presence of a conserved Trp-Ser-Xaa-Trp-Ser motif in the C-terminal part. The receptors consist of two polypeptide chains. Class I receptors can be sub-divided into the GM-CSF sub-family (which includes IL-3, IL-5, GM-CSF, GCSF) and IL-6 sub-family (which includes IL-6, IL-11 and IL-12). In the IL-6 sub-family there is a common tranduscing subunit (gp130) that associates with one or two different cytokine subunits. There is a further sub-family referred to as the IL-2 sub-family (includes IL-2, IL-4, IL-7, IL-9 and IL-15. The repeated Cys motif is also present in Class 2 (interferon receptor family) the ligands of which are α, β and y interferons but lack the conserved Trp-Ser- Xaa-Trp-Ser motif.
Human leptin is a 16kD protein hormone encoded by the lep gene in humans and the ob gene in mice. Leptin acts through the leptin receptor which is a single transmembrane receptor of the cytokine family. There is a single gene that encodes leptin in humans which includes three exons and two introns and spans about 18kb of genomic DNA. Leptin links nutritional status and the immune system to control, inter alia, appetite and the immune function. The existence of mutations in either leptin or leptin receptor can result in an obese phenotype with attendant secondary symptoms associated with obesity (e.g. heart disease, diabetes type II). Leptin is mainly produced by adipose tissue in proportion to the body mass index (BMI) and, at lower levels, by organs such as the stomach and placenta. Leptin regulates body weight through inhibition of food intake and stimulation of energy expenditure. Moreover, leptin affects both the innate and adaptive immunity. On innate immunity, leptin modulates the activity of neutrophils, increases the phagocytosis of monocytes/macrophages and enhances the secretion of inflammatory mediators of the acute-phase response. On adaptive immunity, leptin promotes proliferation and interleukin 2 (IL-2) secretion by naϊve T cells whereas on memory T cells, it promotes the switch towards T helper 1 (Th1) immune response by increasing interferon-γ (INF-γ) and tumor necrosis factor- α (TNF- α secretion). If leptin expression and/or production is perturbed then the pathological manifestation of disease is complicated with effects on energy metabolism and immune status. Apart from the established linkage to obesity, reduction in leptin is associated with infertility, osteoporosis and immune suppression.
This disclosure relates to the identification of leptin recombinant forms that have improved pharmacokinetics (PK) and activity. The new leptin molecules have biological activity, form dimers and have improved stability.
According to an aspect of the invention there is provided a nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide that has the activity of leptin comprising a leptin polypeptide linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
According to an aspect of the invention there is provided a fusion polypeptide comprising: the amino acid sequence of the leptin polypeptide, or active part thereof linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
In a preferred embodiment of the invention said fusion polypeptide comprises two leptin binding domains.
In a further preferred embodiment of the invention said fusion polypeptide comprises an immunoglobulin-like domain.
In a preferred embodiment of the invention said fusion polypeptide comprises at least one cytokine-like homology domain; preferably two cytokine-like homology domains.
In a yet further preferred embodiment of the invention said fusion polypeptide comprises at least one fibronectin III binding domain; preferably two fibronectin III binding domains.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 428-535 of SEQ ID NO: 41.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 536-635 of SEQ ID NO: 41. In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 326-437 of SEQ ID NO: 41.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 62-178 of SEQ ID NO: 41.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 235-325 of SEQ ID NO: 41.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 639-732 of SEQ ID NO: 41.
In a preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 734-829 of SEQ ID NO: 41.
In a further preferred embodiment of the invention said fusion polypeptide comprises amino acid residues 428-635 of SEQ ID NO: 41.
In a preferred embodiment of the invention said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned amino-terminal to said leptin binding domain in said fusion polypeptide.
In a preferred embodiment of the invention said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned carboxyl-terminal to said leptin binding domain in said fusion polypeptide.
In a preferred embodiment of the invention said leptin polypeptide is linked to at least one binding domain of the leptin receptor polypeptide by a peptide linker; preferably a flexible peptide linker.
In a preferred embodiment of the invention said peptide linking molecule comprises at least one copy of the peptide GIy GIy GIy GIy Ser.
In a preferred embodiment of the invention said peptide linking molecule comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 copies of the peptide GIy GIy GIy GIy Ser. Preferably said peptide linking molecule consists of 6 copies of the peptide GIy GIy GIy GIy Ser.
Preferably said peptide linking molecule consists of 8 copies of the peptide GIy GIy GIy GIy Ser.
In an alternative embodiment of the invention said polypeptide does not comprise a peptide linking molecule and is a direct fusion of leptin polypeptide and at least one leptin binding domain of the leptin receptor polypeptide.
According to an aspect of the invention there is provided a nucleic acid molecule comprising a nucleic acid sequence selected from: i) a nucleic acid sequence as represented in SEQ ID NO:3 ; ii) a nucleic acid sequence as represented in SEQ ID NO:5; iii) a nucleic acid sequence as represented in SEQ ID NO:7; iv) a nucleic acid sequence as represented in SEQ ID NO:9; v) a nucleic acid sequence as represented in SEQ ID NO:11 ; vi) a nucleic acid sequence as represented in SEQ ID NO: 13; vii) a nucleic acid sequence as represented in SEQ ID NO:15; viii) a nucleic acid sequence as represented in SEQ ID NO:17; ix) a nucleic acid sequence as represented in SEQ ID NO: 19; x) a nucleic acid sequence as represented in SEQ ID NO:21 ; xi) a nucleic acid sequence as represented in SEQ ID NO:23; xii) a nucleic acid sequence as represented in SEQ ID NO:25; xiii) a nucleic acid sequence as represented in SEQ ID NO:27; a nucleic acid molecule comprising a nucleic sequence that hybridizes under stringent hybridization conditions to SEQ ID NO: 3, 5, 7, 9, 11 , 13, 15, 17, 19, 21 , 23, 25 or 27 and which encodes a polypeptide that has leptin receptor modulating activity.
In a preferred embodiment of the invention said nucleic acid molecule encodes a leptin agonist.
In an alternative preferred embodiment of the invention said nucleic acid molecule encodes a leptin antagonist. Hybridization of a nucleic acid molecule occurs when two complementary nucleic acid molecules undergo an amount of hydrogen bonding to each other. The stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acid molecules used. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY1 2001); and Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes Part I1 Chapter 2 (Elsevier, New York, 1993). The Tm is the temperature at which 50% of a given strand of a nucleic acid molecule is hybridized to its complementary strand. The following is an exemplary set of hybridization conditions and is not limiting:
Very High Stringency (allows sequences that share at least 90% identity to hybridize) Hybridization: 5x SSC at 65°C for 16 hours
Wash twice: 2x SSC at room temperature (RT) for 15 minutes each
Wash twice: 0.5x SSC at 65°C for 20 minutes each
High Stringency (allows seguences that share at least 80% identity to hybridize) Hybridization: 5x-6x SSC at 65°C-70°C for 16-20 hours
Wash twice: 2x SSC at RT for 5-20 minutes each
Wash twice: 1 x SSC at 55°C-70°C for 30 minutes each
Low Stringency (allows seguences that share at least 50% identity to hybridize) Hybridization: 6x SSC at RT to 55°C for 16-20 hours
Wash at least twice: 2x-3x SSC at RT to 55°C for 20-30 minutes each.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO:3 .
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 5.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 7. In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 9.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 11.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 13.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 17.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 19.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 21.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 23.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 25.
In a preferred embodiment of the invention said nucleic acid molecule comprises or consists of a nucleic acid sequence as represented in SEQ ID NO: 27.
According to an aspect of the invention there is provided a polypeptide encoded by the nucleic acid according to the invention.
According to a further aspect of the invention there is provided a polypeptide comprising or consisting of an amino acid sequence as represented in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39 or 40.
According to an aspect of the invention there is provided a homodimer consisting of two polypeptides wherein each of said polypeptides comprises: i) a first part comprising leptin, or a receptor binding domain thereof, optionally linked by a peptide linking molecule to ii) a second part comprising at least one leptin binding domain or part thereof, of the leptin receptor.
In a preferred embodiment of the invention said homodimer comprises two polypeptides comprising or consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39 or 40.
According to a further aspect of the invention there is provided a vector comprising a nucleic acid molecule according to the invention.
In a preferred embodiment of the invention said vector is an expression vector adapted to express the nucleic acid molecule according to the invention.
A vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection. Preferably the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell. The vector may be a bi- functional expression vector which functions in multiple hosts. By "promoter" is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in eukaryotic or prokaryotic cells. "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.
In a preferred embodiment the promoter is a constitutive, an inducible or regulatable promoter.
According to a further aspect of the invention there is provided a cell transfected or transformed with a nucleic acid molecule or vector according to the invention.
Preferably said cell is a eukaryotic cell. Alternatively said cell is a prokaryotic cell. In a preferred embodiment of the invention said cell is selected from the group consisting of; a fungal cell (e.g. Pichia spp, Saccharomyces spp, Neurospora spp); insect cell (e.g. Spodoptera spp); a mammalian cell (e.g. COS cell, CHO cell); a plant cell.
According to a further aspect of the invention there is provided a pharmaceutical composition comprising a polypeptide according to the invention including an excipient or carrier.
In a preferred embodiment of the invention said pharmaceutical composition is combined with a further therapeutic agent.
When administered the pharmaceutical composition of the present invention is administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
The pharmaceutical compositions of the invention can be administered by any conventional route, including injection. The administration and application may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, intra-articuar, subcutaneous, topical (eyes), dermal (e.g a cream lipid soluble insert into skin or mucus membrane), transdermal, or intranasal.
Pharmaceutical compositions of the invention are administered in effective amounts. An "effective amount" is that amount of pharmaceuticals/compositions that alone, or together with further doses or synergistic drugs, produces the desired response. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods.
The doses of the pharmaceuticals compositions administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject (i.e. age, sex). When administered, the pharmaceutical compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. When used in medicine salts should be pharmaceutically acceptable, but non- pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
The pharmaceutical compositions may be combined, if desired, with a pharmaceutically- acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances that are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficacy.
The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.
The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as syrup, elixir or an emulsion.
Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation that is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 , 3-butane diol. Among the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
According to a further aspect of the invention there is provided a method to treat a human subject suffering from a condition that would benefit from administration of a leptin agonist comprising administering an effective amount of at least one polypeptide according to the invention.
In a preferred method of the invention said condition is obesity.
In a further preferred method of the invention said condition is an obesity related condition.
In a preferred method of the invention said obesity related condition is type Il diabetes. In a preferred method of the invention said obesity related condition is heart disease.
In an alternative preferred method of the invention said condition is immune suppression.
According to a further aspect of the invention there is provided a method to treat a human subject suffering from a condition that would benefit from administration of a leptin antagonist comprising administering an effective amount of at least one polypeptide according to the invention.
In a preferred method of the invention said condition is anorexia. In a further preferred method of the invention said condition is an autoimmune disease.
In a preferred method of the invention said autoimmune disease is selected from the group consisting of: multiple sclerosis, type 1 diabetes, autoimmune thyroid disease, autoimmune hepatitis, rheumatoid arthritis, autoimmune colitis, crohns disease, celiac disease, autoimmune nephritis, autoimmune neuropathy (guillan Barre), encephalopathy (Rasmussen), fibrosing alveolitis.
In a preferred method of the invention said polypeptide is administered intravenously.
In an alternative preferred method of the invention said polypeptide is administered subcutaneously.
In a further preferred method of the invention said polypeptide is administered at two day intervals; preferably said polypeptide is administered at weekly, 2 weekly or monthly intervals.
According to a further aspect of the invention there is provided a monoclonal antibody that binds the polypeptide or dimer according to the invention.
Preferably said monoclonal antibody is an antibody that binds the polypeptide or dimer but does not specifically bind leptin or leptin receptor individually.
The monoclonal antibody binds a conformational antigen presented either by the polypeptide of the invention or a dimer comprising the polypeptide of the invention.
In a further aspect of the invention there is provided a method for preparing a hybridoma cell-line producing monoclonal antibodies according to the invention comprising the steps of: i) immunising an immunocompetent mammal with an immunogen comprising at least one polypeptide according to the invention; ii) fusing lymphocytes of the immunised immunocompetent mammal with myeloma cells to form hybridoma cells; iii) screening monoclonal antibodies produced by the hybridoma cells of step
(ii) for binding activity to the polypeptide of (i); iv) culturing the hybridoma cells to proliferate and/or to secrete said monoclonal antibody; and v) recovering the monoclonal antibody from the culture supernatant.
Preferably, the said immunocompetent mammal is a mouse. Alternatively, said immunocompetent mammal is a rat.
The production of monoclonal antibodies using hybridoma cells is well-known in the art. The methods used to produce monoclonal antibodies are disclosed by Kohler and Milstein in Nature 256, 495-497 (1975) and also by Donillard and Hoffman, "Basic Facts about Hybridomas" in Compendium of Immunology V.ll ed. by Schwartz, 1981, which are incorporated by reference.
According to a further aspect of the invention there is provided a hybridoma cell-line obtained or obtainable by the method according to the invention.
Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", means "including but not limited to", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
An embodiment of the invention will now be described by example only and with reference to the following figures:
Table 1 LR fusion nomenclature; Table 2 Expression levels of the leptin LR-fusions as determined by ELISA using antibodies against the leptin receptor, (nd = not detectable)
Figure 1a is the nucleic acid sequence of bacterial expressed leptin; Figure 1b is the amino acid sequence;
Figure 2a is the nucleic acid sequence of LR 2A1 ; Figure 2b is the amino acid sequence of LR 2A1 ;
Figure 3a is the nucleic acid sequence of LR 2A1 ; Figure 2b is the amino acid sequence of LR 2A1 adapted for bacterial expression;
Figure 4a is the nucleic acid sequence of LR 2B1 ; Figure 2b is the amino acid sequence of LR 2B1 ;
Figure 5a is the nucleic acid sequence of LR 2D1 ; Figure 2b is the amino acid sequence of LR 2D1 ;
Figure 6a is the nucleic acid sequence of LR 2E1 ; Figure 2b is the amino acid sequence of LR 2E1 ;
Figure 7a is the nucleic acid sequence of LR 2F1 ; Figure 2b is the amino acid sequence of LR 2F1 ;
Figure 8a is the nucleic acid sequence of LR 2G1 ; Figure 2b is the amino acid sequence of LR 2G1;
Figure 9a is the nucleic acid sequence of LR 2H1 ; Figure 2b is the amino acid sequence of LR 2H1 ;
Figure 10a is the nucleic acid sequence of LR 211 ; Figure 2b is the amino acid sequence of LR 211 ;
Figure 11a is the nucleic acid sequence of LR 2J1 ; Figure 2b is the amino acid sequence of LR 2J1 ; Figure 12a is the nucleic acid sequence of LR 2K1 ; Figure 2b is the amino acid sequence of LR 2K1 ;
Figure 13a is the nucleic acid sequence of LR 2L1 ; Figure 2b is the amino acid sequence of LR 2L1 ;
Figure 14 is the nucleic acid sequence of LR 2M1 ; Figure 2b is the amino acid sequence of LR 2M1 ;
Figure 15 a) The leptin binding domain (LBD) is ligated into the expression vector pSecTag to generate pSecTaglinkSSLBD. b) leptin is ligated into pSecTaglinkSSLBD to generate pSecTag2A1(lm). c) DNA is synthesised and ligated into pSecTag2A1(lm) to introduce a (G4S)5;
Figure 16 Western blot of media from CHO cells expressing leptin LR-fusion. The contents of the lanes are 1 2A1 expression; 2.2B1 expression; 3 2D1 expression; 4. Markers (20, 25, 37, 50, 75, 100, 150, 200 kDa). The western blot was probed with antibodies against leptin.
Figure 17 a) The leptin receptor extracellular domains (ObRex) are ligated into the expression vector pSecTag to generate pSecTaglinkSSObRex. b) leptin is ligated into pSecTaglinkSSObRex to generate pSecTag2B1 (lm). c) DNA is synthesised and ligated into pSecTag2B1 (lm) to introduce a (G4S)5;
Figure 18 a) PCR was used to generate DNA consisting of the gene of interest flanked by suitable restriction sites (contained within primers R1-4). b) The PCR products were ligated into a suitable vector either side of the linker region, c) The construct was then modified to introduce the correct linker, which did not contain any unwanted sequence (i.e. the non-native restriction sites);
Figure 19 a) Oligonucleotides were designed to form partially double-stranded regions with unique overlaps and, when annealed and processed would encode the linker with flanking regions which would anneal to the ligand and receptor, b) PCRs were performed using the "megaprimer" and terminal primers (R1 and R2) to produce the LR-fusion gene. The R1 and R2 primers were designed so as to introduce useful flanking restriction sites for ligation into the target vector; Figure 20 is the amino acid sequence of full length leptin receptor;
Figure 21 is a schematic diagram of the leptin LR-fusion constructs;
Figure 22 is an Immuno-blot analysis of CHO FIp-In stable cell lines expressing 2A1 , 2B1 and 2D1 constructs. Lane M = Markers (at 250, 150, 100, 75, 50, 37, 25 and 2OkDa); Lane 1= CHO FIp-In control cells, Lane 2 = 2A1 expression media, Lane 3 = 2B1 expression media, Lane 4 = 2D1 expression media;
Figure 23 is expression of 2A1Ecopt. A) Coomassie stained gels showing 2A1Ecopt expression. Lane M = Markers (at 250, 150, 100, 75, 50, 37, 25, 20 and 15kDa); Lane 1 = Expression at induction; Lane 2 = Expression 4 hours post-induction; Lane 3 = Expression after overnight incubation, post-induction; Lane 4 = insoluble fraction of 2A1Ecopt expressing cells; Lane 5 = soluble fraction of 2A1 Ecopt expressing cells. B) Immuno-blot of 2A1Ecopt expression. Lane M = Markers (at 250, 150, 100, 75, 50, 37, 25, 20 and 15kDa); Lane 1 = Expression at induction; Lane 2 = Expression 4 hours post- induction; Lane 3 = Expression after overnight incubation, post-induction;
Figure 24 is a Coomassie stained SDS-PAGE gel of the inclusion body prep for 2A1 Ecopt. Lane M = Markers (at 250, 150, 100, 75, 50, 37, 25 and 2OkDa); Lane 1= E. coli BL21(DE3):2A1Ecopt whole cell; Lane 2 = Cell lysate - soluble fraction; Lane 3 = cell lysate - insoluble fraction; Lanes 4-7 = 2% sodium deoxychlate washes 1-4; Lanes 8-9 = water washes 1-2; Lane 10 = Inclusion body prep.
Figure 25 is an In vitro bioassay of crude media from CHO FIp-In cells expressing 2A1. Crude media (10x concentrate) from CHO FIp-In cells expressing 2A1 was used to stimulate the cells in the leptin in vitro bioassay. The media gave agonistic activity, media from cells not expressing 2A1 gave no activity (black columns); and
Figure 26 is an In vitro bioassay of the purified 2A1Ecopt. Refolded 2A1 Ecopt samples which showed a single band at the correct size for 2A1Ecopt in the immuno-blots were used to stimulate the cells in the leptin in vitro bioassay. The samples showed agonistic activity. Materials and Methods
In vitro testing
In vitro methods to detect and assess the activity of leptin are known in the art. For example see Liu et al (Endocrinology (1997) 138, 8: p3548-3554); White et al (J. Biol Chemistry (1997) 272(7): p4065-4071); and Maamra et al (Endocrinology (2007) 142(10): 4389-4393) which each describe, inter alia, the expression of leptin receptor in a cell based assay.
In addition Leptin LR-fusions were tested for in vitro activity using a dual-luciferase bioassay. Briefly, MCF-7 mammalian cells were transfected with plasmids expressing firefly luciferase induced by SIE, leptin receptor (ObR), STAT3 and Renilla luciferase (the latter three proteins are constitutively expressed). Twenty-four hours later the cells are stimulated for six hours with the leptin LR-fusion. The cells were lysed and the Firefly luciferase activity measured, this is proportional to the stimulation of the leptin receptor by the LR-fusion. Dividing this value by the activity of the constitutively expressed Renilla luciferase gives an activity corrected for experimental error.
In vivo testing
In vivo animal models are known in the art. The ob/ob mouse model (Zhang et al Nature
(1994) 372: 425-432) is homozygous for a leptin mutation and has been used to assess the activity of leptin agonists and antagonist; see Chehab et al (Nature Genetics (1996)
12: 318-320); Lord et al (Nature (1998) 394: 897-901); and Pellymounter et al (Science
(1995) 269: 540-542).
Immunological testing
Immunoassays that measure the binding of ligand or receptor to polyclonal and monoclonal antibodies are known in the art. Commercially available antibodies are available to detect the ligand or receptor in samples and also for use in competitive inhibition studies. For example, see http://www.abcam.com/index.html. Abeam PLC. Recombinant Production of fusion proteins
The components of the fusion proteins were generated by PCR using primers designed to anneal to the ligand or receptor and to introduce suitable restriction sites for cloning into the target vector (Fig X1a). The template for the PCR comprised the target gene and was obtained from IMAGE clones, cDNA libraries or from custom synthesised genes. Once the ligand and receptor genes with the appropriate flanking restriction sites had been synthesised, these were then ligated either side of the linker region in the target vector (Fig X1b). The construct was then modified to contain the correct linker without flanking restriction sites by the insertion of a custom synthesised length of DNA between two unique restriction sites either side of the linker region, by mutation of the linker region by ssDNA modification techniques, by insertion of a primer duplex/multiplex between suitable restriction sites or by PCR modification (FigXic).
Alternatively, the linker with flanking sequence, designed to anneal to the ligand or receptor domains of choice, was initially synthesised by creating an oligonucleotide duplex and this processed to generate double-stranded DNA (Fig X2a). PCRs were then performed using the linker sequence as a "megaprimer", primers designed against the opposite ends of the ligand and receptor to which the "megaprimer" anneals to and with the ligand and receptor as the templates. The terminal primers were designed with suitable restriction sites for ligation into the expression vector of choice (Fig X2b).
Expression and Purification of Fusion Proteins
Expression was carried out in a suitable system (e.g. mammalian CHO cells, E. coli, etc.) and this was dependant on the vector into which the LR-fusion gene was generated. Expression was then analysed using a variety of methods which could include one or more of SDS-PAGE, Native PAGE, western blotting, ELISA.
Once a suitable level of expression was achieved the RL-fusions were expressed at a larger scale to produce enough protein for purification and subsequent analysis.
Purification was carried out using a suitable combination of one or more chromatographic procedures such as ion exchange chromatography, hydrophobic interaction chromatography, ammonium sulphate precipitation, gel filtration, size exclusion and/or affinity chromatography (using nickel/cobalt-resin, antibody-immobilised resin and/or ligand/receptor-immobilised resin).
Purified protein was analysed using a variety of methods which could include one or more of Bradford's assay, SDS-PAGE1 Native PAGE, western blotting, ELISA.
Characterisation of LR-fusions
Denaturing PAGE, native PAGE gels and western blotting were used to analyse the fusion polypeptides and western blotting performed with antibodies non-conformationally sensitive to the LR-fusion. Native solution state molecular weight information can be obtained from techniques such as size exclusion chrmoatography using a Superose G200 analytical column and analytical ultracenthfugation.
Construction of LR-fusions
The 2A1 , 2B1 and 2D1 genes were synthesised by generating the Ob, LBD, ObREc and linker components with unique, compatible restriction sites at either end and ligating them together to form the complete gene. Extraneous sequence (i.e. the restriction sites) in 2B1 and 2D1 were subsequently removed by ligating in custom synthesised DNA fragments (Genecust, France) between unique restriction sites within the Ob, LBD and ObREc genes, this generated 2B2 and 2D2. The 2A1 Ecopt gene was generated by custom DNA synthesis (Genecust, France) and ligated into pET21a+. The 2A1 Ecopt sequence is codon optimised for expression in E. coli and has a C-terminal His tag.
Expression of LR-fusions
Mammalian expression:
Stable cell lines were generated using a modified Invitrogen vector pSecTag-V5/FRT- Hist in 6-well plates using Fugene-6 as the transfection reagent. The CHO FIp-In cells were co-transfected with the expression vector and pOG44, a plasmid that expresses flp recombinase an enzyme which causes the recombination of the LR-fusion gene into a "hot-spot" of the cell chromosome. Hygromycin B was used to select for cells with positive recombinants. Once the stable cell lines had been established they were grown on 75cm2 culture plates, at a confluency of 50-70% the media was changed to serum free media. The cultures were incubated for a further 2-4 days after which media samples were taken. These were run on 13% SDS-PAGE gels and transferred to PVDF membrane for immuno-blotting. After blocking in 5% (w/v) milk protein in PBS + 0.05% (v/v) Tween 20, sample detection was carried out using a specific anti-leptin antibody together with a Horse Radish Peroxidase (HRP) conjugated secondary antibody. Visualisation was by chemiluminesence on photographic film using an HRP detection kit.
The immuno-blots showing the expression of the LR-fusions from the mammalian system are shown in Figure 22.
E. co// expression: pET21a+:2A1 Ecopt was transformed into chemically competent E. coli BL21 (DE3) cells. Clones expressing 2A1 Ecopt were then grown in LB media supplemented with carbenicillin (100μg/ml) and grown on a flat bed shaker at room temperature. Induction was performed with 1 mM IPTG at an OD6oo of 0.4 and the culture grown for overnight.
The cells were then harvested and lysed, samples were then run on SDS-PAGE gels and coomassie stained or immuno-blotted.
The immuno-blots showing the expression of the LR-fusions from the E.coli system are shown in Figure 23.
Purification of LR-fusions
E. coli expressed LR-fusion purification (2A1 Ecopt)
2A1 Ecopt was expressed in E. coli BL21 (DE3) cells from the plasmid pET21a+:2A1 Ecopt.
2A1 Ecopt was purified using a Ni-Probond resin column. The insoluble fraction of the lysed cells was washed four times with 2% sodium deoxycholate and the two times with distilled water to give an inclusion body prep. This step removed most of the contaminating proteins giving >80% purity for 2A1 Ecopt; Figure 24. Statistics
Two groups were compared with a Student's test if their variance was normally distributed or by a Student-Satterthwaite's test if not normally distributed. Distribution was tested with an F test. One-way ANOVA was used to compare the means of 3 or more groups and if the level of significance was p<0.05 individual comparisons were performed with Dunnett's tests. All statistical tests were two-sided at the 5% level of significance and no imputation was made for missing values.
Example 1 : 2A1
DNA encoding the leptin binding domain (LBD) domains of the leptin receptor (ObR) flanked by BamHI and Hindlll was produced by PCR. This was then ligated into a modified pSecTag-FRT-V5-His TOPO vector to produce pSecTagLinkSSLBD (Fig 15a). DNA encoding leptin flanked by Nhel and BamHI was produced by PCR using the primers; NheObssF (5'-gggaaagctagccaccatgcattggggaaccctgtgcg-3') and ObBamR (5'-gggaaaggatccgcacccagggctgaggtcc-3'). This was ligated into pSecTagLinkSSLBD to produce pSecTag2A1 (Im) (Fig 15b). The linker region was custom synthesised between AIeI and Nsil restriction sites and this inserted into pSecTag2A1(lm) to give pSecTag2A1 stop (Fig 15c). pSecTag2A1 stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. However western blot of the expression media, using antibodies against leptin, showed 2A1 was expressed (Fig 16). 2A1 was also expressed in Escherichia coli cells. The amino acid sequence for 2A1 was back-translated with optimisation for E. coli codon usage. The codon optimised gene (2A1 Ecopt) was custom gene synthesised and then inserted into the pET21a+ expression vector and the protein expressed from E. coli BL21 (DE3) cells.
Example 2: 2B1
DNA encoding the leptin receptor extracellular domain (ObRex) flanked by BamHI and Hindlll was produced by PCR. This was then ligated into a modified pSecTag-FRT-V5- His TOPO vector to produce pSecTagLinkSSObRex (Fig 17a). DNA encoding leptin flanked by Nhel and BamHI was produced by PCR using the primers; NheObssF (5'- gggaaagctagccaccatgcattggggaaccctgtgcg-3') and ObBamR (5'- gggaaaggatccgcacccagggctgaggtcc-3'). This was ligated into pSecTagLinkSSObRex to produce pSecTag2B1 (Im) (Fig 17b). The linker region was custom synthesised between AIeI and BstBI restriction sites and this inserted into pSecTag2B1(lm) to give pSecTag2B1stop (Fig 17c). pSecTag2B1stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. Expression levels were determined to be in the low ng/ml levels as measured by ELISA using antibodies against ObR (Table 2). However these expression levels may have been underestimated by the ELISA since the western blot of the expression media suggests that higher levels of expression have been achieved (Fig 16).
Example 3: 2D1
pSecTag2D1stop was synthesised in a similar way to pSecTag2B1stop, above. pSecTag2B1stop was transfected into Chinese Hamster Ovary (CHO) cells and transient and stable expression cell lines developed. Expression levels were determined to be in the low ng/ml levels as measured by ELISA using antibodies against ObR (Table 2). However these expression levels may have been underestimated by the ELISA since the western blot of the expression media suggests that higher levels of expression have been achieved (Fig 16).
Example 4 In vitro bioassav results
The in vitro bioassay utilises a dual-luciferase reporter system to measure the activity of stimulated MCF-7 cells.
MCF-7 cells were transfected with plasmid expressing ObR, STAT5, SIE and Renilla luciferase. Activation of the ObR caused an inducible, proportional expression of firefly luciferase via STAT3 and SIE; the Renilla luciferase was constitutively expressed and acted as a control to normalise the firefly luciferase activity measurement. Both the firefly and Renilla luciferase were measured using the Dual-Luciferase Reporter Assay System (Promega) and a luminometer. Dividing the firefly luciferase measurement by the Renilla luciferase measurement gave a corrected activity (i.e. correction for differences between samples such as cell density and transfection efficiency). The corrected activity was then divided by the activity of un-stimulated cells to give a "fold induction" value.
The bioactivity for 2A1 (1Ox concentrate) and 2A1Ecopt (purified) is shown in Figures 25 and 26 respectively.

Claims

Claims
1 A nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide that has the activity of leptin comprising a leptin polypeptide linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
2. A fusion polypeptide comprising: the amino acid sequence of the leptin polypeptide, or active part thereof linked, directly or indirectly, to at least one leptin binding domain of the leptin receptor polypeptide.
3. A fusion polypeptide according to claim 2 wherein said polypeptide comprises two leptin binding domains.
4. A fusion polypeptide according to claim 2 or 3 wherein said fusion polypeptide comprises an immunoglobulin-like domain.
5. A fusion polypeptide according to any of claims 2-4 wherein said polypeptide comprises at least one cytokine-like homology domain.
6. A fusion polypeptide according to any of claims 2-4 wherein said polypeptide comprises two cytokine-like homology domains.
7. A fusion polypeptide according to any of claims 2-6 wherein said polypeptide comprises at least one fibronectin III binding domain.
8. A fusion polypeptide according to any of claims 2-6 wherein said polypeptide comprises two fibronectin III binding domains.
9. A fusion polypeptide according to any of claims 2-8 wherein said polypeptide comprises amino acid residues 425-535 of SEQ ID NO: 41.
10. A fusion polypeptide according to any of claims 2-9 wherein said polypeptide comprises amino acid residues 536-635 of SEQ ID NO: 41.
11. A fusion polypeptide according to any of claims 2-10 wherein said polypeptide comprises amino acid residues 326-427 of SEQ ID NO: 41.
12. A fusion polypeptide according to any of claims 2-11 wherein said polypeptide comprises amino acid residues 62-178 of SEQ ID NO: 41.
13. A fusion polypeptide according to any of claims 2-12 wherein said polypeptide comprises amino acid residues 235-325 of SEQ ID NO: 41.
14. A fusion polypeptide according to any of claims 2-13 wherein said polypeptide comprises amino acid residues 636-733 of SEQ ID NO: 41.
15. A fusion polypeptide according to any of claims 2-14 wherein said polypeptide amino acid residues 734-829 of SEQ ID NO: 41.
16. A fusion polypeptide according to any of claims 2-15 wherein said polypeptide comprises amino acid residues 428-635 of SEQ ID NO: 41.
17. A fusion polypeptide according to any of claims 2-16 wherein said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned amino-terminal to said leptin binding domain in said fusion polypeptide.
18. A fusion polypeptide according to any of claims 2-16 wherein said leptin polypeptide is linked to at least one leptin binding domain of leptin receptor wherein said leptin polypeptide is positioned carboxyl-terminal to said leptin binding domain in said fusion polypeptide.
19. A fusion polypeptide according to any of claims 2-18 wherein said leptin polypeptide is linked to at least one binding domain of the leptin receptor polypeptide by a peptide linker.
20. A fusion polypeptide according to claim 19 wherein said peptide linking molecule comprises at least one copy of the peptide GIy GIy GIy GIy Ser.
21. A fusion polypeptide according to claim 20 wherein said peptide linking molecule comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 copies of the peptide GIy GIy GIy GIy Ser.
22. A fusion polypeptide according to claim 21 wherein said peptide linking molecule consists of 6 copies of the peptide GIy GIy GIy GIy Ser.
23. A fusion polypeptide according to claim 21 wherein said peptide linking molecule consists of 8 copies of the peptide GIy GIy GIy GIy Ser.
24. A fusion polypeptide according to any of claims 2-18 wherein said fusion polypeptide is a direct fusion of leptin polypeptide and at least one leptin binding domain of the leptin receptor polypeptide.
25. A nucleic acid molecule comprising a nucleic acid sequence selected from: i) a nucleic acid sequence as represented in SEQ ID NO:3 ; ii) a nucleic acid sequence as represented in SEQ ID NO:5; iii) a nucleic acid sequence as represented in SEQ ID NO:7; iv) a nucleic acid sequence as represented in SEQ ID NO:9; v) a nucleic acid sequence as represented in SEQ ID NO:11 ; vi) a nucleic acid sequence as represented in SEQ ID NO: 13; vii) a nucleic acid sequence as represented in SEQ ID NO: 15; viii) a nucleic acid sequence as represented in SEQ ID NO: 17; ix) a nucleic acid sequence as represented in SEQ ID NO: 19; x) a nucleic acid sequence as represented in SEQ ID NO:21 ; xi) a nucleic acid sequence as represented in SEQ ID NO:23; xii) a nucleic acid sequence as represented in SEQ ID NO:25; xiii) a nucleic acid sequence as represented in SEQ ID NO:27; a nucleic acid molecule comprising a nucleic sequence that hybridizes under stringent hybridization conditions to SEQ ID NO: 3, 5, 7, 9, 11 , 13, 15, 17, 19, 21 , 23, 25 or 27 and which encodes a polypeptide that has leptin receptor modulating activity.
26. A nucleic acid molecule according to claim 25 wherein said nucleic acid molecule encodes a leptin agonist.
27. A nucleic acid molecule according to claim 25 wherein said nucleic acid molecule encodes a leptin antagonist.
28 A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 3.
29. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 5.
30. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 7.
31. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 9.
32. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 11.
33. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 13.
34. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 15.
35. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 17.
36. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 19.
37. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 21.
38. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 23.
39. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 25.
40. A nucleic acid molecule according to any of claims 25-27 wherein said nucleic acid molecule comprises a nucleic acid sequence as represented in SEQ ID NO: 27.
41. A polypeptide encoded by the nucleic acid molecule according to any of claims 1 or 25-40.
42. A polypeptide comprising an amino acid sequence as represented in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40.
43. A homodimer consisting of two polypeptides wherein each of said polypeptides comprises: i) a first part comprising leptin, or a receptor binding domain thereof, optionally linked by a peptide linking molecule to ii) a second part comprising at least one leptin binding domain or part thereof, of the leptin receptor.
44. A homodimer according to claim 43 wherein said homodimer comprises two polypeptides comprising SEQ ID NO: of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39 or 40..
45. A vector comprising a nucleic acid molecule according to any of claims 1 or 25- 40.
46. A cell transfected or transformed with a nucleic acid molecule or vector according to any of claims 1 , 25-40 or 45.
47. A cell according to claim 46 wherein said cell is a eukaryotic cell.
48. A cell according to claim 46 wherein said cell is a prokaryotic cell.
49. A pharmaceutical composition comprising a polypeptide according to any of claims 2-24 or 41 or 42 including an excipient or carrier.
50. A pharmaceutical composition according to claim 49 wherein composition is combined with a further therapeutic agent.
51. A method to treat a human subject suffering from a condition that would benefit from administration of a leptin agonist comprising administering an effective amount of at least one polypeptide according to any of claims 2-24 or 41 or 42.
52. The method according to claim 51 wherein said condition is obesity.
53. The method according to claim 51 wherein said condition is an obesity related condition.
54. The method according to claim 53 wherein said obesity related condition is type Il diabetes.
55. The method according to claim 53 wherein said obesity related condition is heart disease.
56. The method according to claim 51 wherein said condition is immune suppression.
57. A method to treat a human subject suffering from a condition that would benefit from administration of a leptin antagonist comprising administering an effective amount of at least one polypeptide according to any of claims 2-24 or 40 or 41.
58. The method according to claim 57 wherein said condition is anorexia.
59. The method according to claim 57 wherein said condition is an autoimmune disease.
60. The method according to claim 59 wherein said autoimmune disease is selected from the group consisting of: multiple sclerosis, type 1 diabetes, autoimmune thyroid disease, autoimmune hepatitis, rheumatoid arthritis, autoimmune colitis, crohns disease, celiac disease, autoimmune nephritis, autoimmune neuropathy, encephalopathy, fibrosing alveolitis.
61. The method according to any of claims 51-60 wherein said polypeptide is administered intravenously.
62. The method according to any of claims 51-60 wherein said polypeptide is administered subcutaneously.
63. The method according to any of claims 51-62 wherein said polypeptide is administered at two day intervals.
64. The method according to any of claims 51-62 wherein said polypeptide is administered at weekly intervals.
65. The method according to any of claims 51-62 wherein said polypeptide is administered at 2 weekly intervals.
66. The method according to any of claims 51-62 wherein said polypeptide is administered at monthly intervals.
67. A monoclonal antibody that binds the polypeptide or dimer according to any of claims 2-24 or 40, 41 or 43 or 44.
68. The antibody according to claim 67 wherein said monoclonal antibody is an antibody that binds the polypeptide or dimer but does not specifically bind leptin or leptin receptor individually.
69. A method for preparing a hybridoma cell-line producing monoclonal antibodies according to the invention comprising the steps of: i) immunising an immunocompetent mammal with an immunogen comprising at least one polypeptide according to the invention; ii) fusing lymphocytes of the immunised immunocompetent mammal with myeloma cells to form hybridoma cells; iii) screening monoclonal antibodies produced by the hybridoma cells of step (ii) for binding activity to the polypeptide of (i); iv) culturing the hybridoma cells to proliferate and/or to secrete said monoclonal antibody; and v) recovering the monoclonal antibody from the culture supernatant.
70. A method according to claim 69 wherein said immunocompetent mammal is a mouse or rat.
71. A hybridoma cell-line obtained or obtainable by the method according to claim 69 or 70.
72. A diagnostic test to detect a polypeptide according to the invention in a biological sample comprising:
i) providing an isolated sample to be tested; ii) contacting said sample with a ligand that binds the polypeptide or dimer according to any of claims 2-24 or 40 or 41 or 43 or 44.; and iii) detecting the binding of said ligand in said sample.
73. A method according to claim 72 wherein said ligand is an antibody.
74. A method according to claim 73 wherein said antibody is a monoclonal antibody.
PCT/GB2008/002489 2007-08-03 2008-07-23 Leptin fusion proteins WO2009019427A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN200880110351A CN101827858A (en) 2007-08-03 2008-07-23 Leptin fusion proteins
JP2010519503A JP2010535486A (en) 2007-08-03 2008-07-23 Leptin fusion protein
EP08776011A EP2185585A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins
US12/671,979 US20110092417A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0715216.8A GB0715216D0 (en) 2007-08-03 2007-08-03 Leptin
GB0715216.8 2007-08-03
US95636007P 2007-08-16 2007-08-16
US60/956,360 2007-08-16

Publications (1)

Publication Number Publication Date
WO2009019427A1 true WO2009019427A1 (en) 2009-02-12

Family

ID=38529304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002489 WO2009019427A1 (en) 2007-08-03 2008-07-23 Leptin fusion proteins

Country Status (6)

Country Link
US (1) US20110092417A1 (en)
EP (1) EP2185585A1 (en)
JP (1) JP2010535486A (en)
CN (1) CN101827858A (en)
GB (1) GB0715216D0 (en)
WO (1) WO2009019427A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
CN109942716A (en) * 2019-04-08 2019-06-28 河南师范大学 A kind of leptin fusion protein and its preparation method and application for treating metabolic disease
CN111848774A (en) * 2020-08-05 2020-10-30 武汉海特生物制药股份有限公司 Preparation method of metreleptin

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013007388B1 (en) 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc POLYPEPTIDE HAVING ALBUMIN AND LEPTIN BINDING DOMAIN, ITS USE IN THE TREATMENT OF DISEASES, AS WELL AS A PHARMACEUTICAL COMPOSITION THAT COMPRISES IT
JP6006309B2 (en) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ Engineered polypeptides with increased duration of action and reduced immunogenicity
US20140256621A1 (en) * 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
AU2017359439A1 (en) 2016-11-08 2019-05-23 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
EP3773713A1 (en) 2018-04-06 2021-02-17 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002552A2 (en) * 1997-07-10 1999-01-21 Yeda Research And Development Co. Ltd. Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
WO2006010891A2 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
WO2007080404A2 (en) * 2006-01-12 2007-07-19 Asterion Limited Leptin ligand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002552A2 (en) * 1997-07-10 1999-01-21 Yeda Research And Development Co. Ltd. Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
WO2006010891A2 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
WO2007080404A2 (en) * 2006-01-12 2007-07-19 Asterion Limited Leptin ligand

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 1 February 1995 (1995-02-01), "RecName: Full=Leptin; AltName: Full=Obesity factor; AltName: Full=Obese protein; Flags: Precursor;", XP002501728, retrieved from EBI accession no. UNIPROT:P41159 Database accession no. P41159 *
DATABASE UniProt [online] 1 February 1996 (1996-02-01), "RecName: Full=Leptin receptor; Short=LEP-R; AltName: Full=OB receptor; Short=OB-R; AltName: Full=HuB219; AltName: CD_antigen=CD295; Flags: Precursor;", XP002501729, retrieved from EBI accession no. UNIPROT:P48357 Database accession no. P48357 *
FAZELI ET AL: "Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 312, no. 1-2, 30 May 2006 (2006-05-30), pages 190 - 200, XP005479381, ISSN: 0022-1759 *
FONG T M ET AL: "Localization of leptin binding domain in the leptin receptor", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 53, no. 2, 1 February 1998 (1998-02-01), pages 234 - 240, XP002329230, ISSN: 0026-895X *
WILKINSON IAN R ET AL: "A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 9, 1 September 2007 (2007-09-01), pages 1108 - 1113, XP009089546, ISSN: 1078-8956 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN109942716A (en) * 2019-04-08 2019-06-28 河南师范大学 A kind of leptin fusion protein and its preparation method and application for treating metabolic disease
CN109942716B (en) * 2019-04-08 2023-05-12 河南师范大学 Leptin fusion protein for treating metabolic diseases and preparation method and application thereof
CN111848774A (en) * 2020-08-05 2020-10-30 武汉海特生物制药股份有限公司 Preparation method of metreleptin
CN111848774B (en) * 2020-08-05 2022-05-10 武汉海特生物制药股份有限公司 Preparation method of metreleptin

Also Published As

Publication number Publication date
JP2010535486A (en) 2010-11-25
GB0715216D0 (en) 2007-09-12
US20110092417A1 (en) 2011-04-21
EP2185585A1 (en) 2010-05-19
CN101827858A (en) 2010-09-08

Similar Documents

Publication Publication Date Title
US20110092417A1 (en) Leptin fusion proteins
Dumoutier et al. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22
Hermanns et al. Non-redundant signal transduction of interleukin-6-type cytokines: the adapter protein Shc is specifically recruited to the oncostatin M receptor
Hilton et al. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor.
Wang et al. Expression cloning and characterization of the TGF-β type III receptor
Hammacher et al. Structure‐function analysis of human IL‐6: identification of two distinct regions that are important for receptor binding
JP3559281B2 (en) CD27 ligand
KR100891509B1 (en) Linkers
JP4660062B2 (en) Binder
Deller et al. Crystal structure and functional dissection of the cytostatic cytokine oncostatin M
Lock et al. Histidine-367 of the human common beta chain of the receptor is critical for high-affinity binding of human granulocyte-macrophage colony-stimulating factor.
JPH06506598A (en) Parathyroid hormone receptor and the DNA that encodes it
US20110182848A1 (en) Granulocyte colony stimulating factor
Mirza et al. The Ig-like domain of human GM-CSF receptor α plays a critical role in cytokine binding and receptor activation
US20110230401A1 (en) Insulin fusion polypeptides
RU2325400C2 (en) Multimers of receptor-binding ligands
JP2023510871A (en) IL2 mutein
Yang et al. Functional characterization of IL-18 receptor subunits, IL-18Rα and IL-18Rβ, and its natural inhibitor, IL-18 binding protein (IL-18BP) in rainbow trout Oncorhynchus mykiss
Taupin et al. Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains
US20110152187A1 (en) Insulin-like growth factor fusion proteins
Han et al. Molecular cloning and characterization of chicken interferon-γ receptor α-chain
EP2185582A2 (en) Erythropoietin fusion proteins
JPWO2001090382A1 (en) Fas ligand fusion protein
JP5272735B2 (en) Biologics
WO1992021754A1 (en) Dna which codes for secretin receptor and polypeptide which is coded for by said dna

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110351.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776011

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010519503

Country of ref document: JP

Ref document number: 12671979

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 778/KOLNP/2010

Country of ref document: IN

Ref document number: 2008776011

Country of ref document: EP